Synthetic antisense oligodeoxynucleotides targeted to human ache

US6121046A · kind A · utility

Assignee

• YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. · IL

Inventors

• Hermona Soreq · Nesher, IL
• Shlomo Seidman · Rishon LeZion, IL
• Fritz Eckstein · Göttingen, DE
• Alon Friedman · Ramat HaSharon, IL
• Daniela Kaufer · Kiryat Ono, IL

Key dates

• Filing date: Dec 12, 1997
• Grant date: Sep 19, 2000
• Expiry date: Dec 12, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/53
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.